← Evidence library

BIB_395

🟢 ViDMe trial (De Smedt 2024 Br J Dermatol) — the DEFINITIVE melanoma-specific RCT on vitamin D supplementation: high-dose VD is SAFE but does NOT improve relapse-free survival, melanoma death, or OS in resected Stage IA–III CM. DIRECTLY anchors the patient's actual 4000 IU/day regimen → justified for bone/general health ONLY, not melanoma prevention.

Evidence grade

A

Tier

1 (Br J Dermatol; randomized double-blind placebo-controlled trial, n=436, melan

Cited by tasks

9, 13, 25

Identifiers

DOI:10.1093/bjd/ljae257 · PMID:38913652

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_395/findings.md (research corpus). This page is a short context summary — not individualised medical advice.